An Evaluation of HER2-Positive Ovarian Carcinoma Xenografts: From a Novel Therapy to a Noninvasive Monitoring Method

Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.


from Mary Ann Liebert, Inc. publishers via xlomafota13 on Inoreader https://ift.tt/2mQwkHC
via IFTTT